Infrastructure, Payment Gaps Persist for Bispecifics in the Community

Why It Matters

If these gaps remain unaddressed, community providers face financial strain and reduced patient access, while payers risk higher downstream costs from delayed or suboptimal therapy.

Key Takeaways

• Step‑up dosing adds unreimbursed staffing costs for community clinics
• Education, standardized language, and reimbursement security are core program pillars
• Hospital‑based observation for early doses complicates outpatient delivery
• Anticipated patient volume surge will outpace current infrastructure
• Payers must fund coordination and monitoring to enable scale

Pulse Analysis

Bispecific antibodies are reshaping the oncology landscape, offering targeted efficacy that rivals traditional monoclonal antibodies. As clinical data push these agents into earlier lines of therapy, manufacturers and payers alike expect a rapid migration from academic hospitals to community oncology sites. This shift promises greater patient convenience but also exposes a readiness gap: many community clinics lack the physical space, infusion capabilities, and specialized staff required to manage complex dosing schedules and toxicity monitoring.

A central operational hurdle is step‑up dosing, where incremental dose escalation mitigates severe adverse events. While clinically essential, the process demands intensive nursing time, pharmacy coordination, and often a brief inpatient observation period. Current reimbursement frameworks treat these activities as ancillary, leaving practices to shoulder the cost. Ajayi’s emphasis on education, standardized clinical language, and guaranteed reimbursement reflects a pragmatic roadmap—training clinicians to anticipate side effects, aligning terminology between outpatient and hospital teams, and securing payer contracts that recognize the true cost of delivery.

Looking ahead, patient eligibility for bispecifics is set to expand dramatically, especially as trials demonstrate benefit in earlier disease stages. Without proactive investment, community practices risk being bottlenecked, forcing patients back to tertiary centers or delaying therapy. Payers will need to redesign prior‑authorization and bundled‑payment models to cover coordination, monitoring, and prophylactic interventions such as immunoglobulin supplementation. Simultaneously, the workforce must be scaled with dedicated oncology pharmacists and infusion nurses trained in bispecific protocols. Aligning financial incentives with operational capacity will be the decisive factor in translating bispecific breakthroughs into real‑world outcomes.